Loading...
A practical guide to the handling and administration of talimogene laherparepvec in Europe
Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a)...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5546812/ https://ncbi.nlm.nih.gov/pubmed/28814886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S133699 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|